A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Inclusion Criteria:

* Patients with a histologic or cytologic diagnosis of intrahepatic cholangiocarcinoma with stage IV;
* Have progressed after systematic chemotherapy/target therapy, or cannot tolerated with first-line treatment;
* The previous treatment and the present trial registration must be at least 2 weeks apart, and they must have recovered from any toxicity of a previous treatment;
* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1;
* Eastern Cooperative Oncology Group performance score (ECOG): 0-2;
* Life expectancy of at least 12 weeks;
* Subjects who understand and voluntarily signed a written informed consent form.

Exclusion Criteria:

* Previous locoregional therapy within 4 weeks prior to enrollment.
* Diagnosed with hepatocellular carcinoma, mixed cell carcinoma and fibrolamellar hepatocellular carcinoma.
* History of other malignancy within 5 years except for non-melanoma skin cancer, cervix in situ carcinoma.
* Prepared for liver transplantation.
* Patients with contraindications (active bleeding, ulcers, intestinal perforation, intestinal obstruction, within 30 days after major surgery, uncontrolled high blood pressure medication, III-IV level cardiac insufficiency, severe liver and kidney dysfunction).
* A previous history of Interstitial pulmonary disease, drug-induced interstitial disease, radiation pneumonitis requiring hormonal therapy or active interstitial lung disease with any clinical evidence.
* Use of CYP3A4 inhibitor within 7 days or CYP3A4 inducer within 12 days prior to enrollment.
* Patients with central nervous system metastases or brain metastasis
* Previous definite diagnosis of neuropsychiatric disturbances, including epilepsy or dementia.
* Pregnant or lactating women.
* Patients with bone metastasis received palliative radiation within 4 weeks prior to enrollment.